Cilostazol Tablets

This product is an antiplatelet drug. It inhibits the activity of phosphodiesterase in platelets and vascular smooth muscle, thereby increasing the cAMP concentration in platelets and smooth muscle, exerting antiplatelet and vasodilatory effects. This product inhibits the initial and secondary aggregation and release reactions of platelets induced by ADP, adrenaline, collagen and arachidonic acid, and is dose-dependent. Oral administration of 100 mg of cilostazol is 7 to 78 times more effective than the corresponding amount of aspirin in inhibiting platelet aggregation in vitro (aspirin is ineffective against initial platelet aggregation). This product does not interfere with the synthesis of vascular protective prostacyclin by vascular endothelial cells. For patients with chronic arterial occlusion, the use of volume plethysmography shows that this product can increase tissue blood flow in the foot and gastrocnemius muscles, increase the blood pressure index of the lower limbs, increase skin blood flow and increase skin temperature of the limbs, and improve intermittent claudication.

The main ingredient of this product is cilostazol, its chemical name is: 6-[4-(1-cyclohexyl-1H pentylenetetrazolium (5,) butoxy) 3,4-dihydro-1H-quinolone (2,) molecular formula: C20H27N5O2 molecular weight: 369.47

This product is white tablets.

It is suitable for the treatment of chronic arterial occlusive disease caused by atherosclerosis, large arteritis, thromboangiitis obliterans, and diabetes. This product can improve chronic ulcers, pain, chills, and intermittent claudication caused by limb ischemia, and can be used as a supplementary treatment after surgical treatment of the above diseases (such as angioplasty, vascular transplantation, sympathectomy) to relieve symptoms.

Oral: Adults, 50-100 mg at a time, twice a day. For young patients, the dose can be increased appropriately if necessary based on symptoms.

1. The main adverse reactions are headache, dizziness and palpitations caused by vasodilation, and some patients may have high blood pressure; 2. The second most common adverse reactions are digestive tract symptoms such as abdominal distension, nausea, vomiting, stomach discomfort, abdominal pain, etc.; 3. A small number of patients developed abnormal liver function, frequent urination, abnormal urea nitrogen, creatinine and uric acid levels after taking the medicine; 4. Allergic symptoms include rash and itching; 5. There have been occasional reports of leukopenia, subcutaneous hemorrhage, gastrointestinal bleeding, epistaxis, hematuria, fundus hemorrhage, etc.

Patients with bleeding disorders (such as hemophilia, capillary fragility, active peptic ulcer, hematuria, hemoptysis, functional uterine bleeding, etc. or other bleeding tendencies).

Precautions for children: The safety of the drug for low birth weight infants, newborns, infants, toddlers, and children has not been established (little experience in use). Precautions for pregnancy and lactation: 1. Pregnant women and women who may become pregnant should not take the drug (in animal (rat) experiments, there are reports of increased abnormal fetuses, low birth weight, and increased mortality); 2. Lactating women should avoid breastfeeding when taking the drug (in animal (rat) experiments, there are reports that the drug enters breast milk). Precautions for the elderly: Generally speaking, elderly patients have low physiological functions, so they should pay attention to reducing the dosage, etc.

Prostaglandin E1 can act synergistically with this product to increase intracellular cyclic adenosine monophosphate and enhance therapeutic efficacy.

Keep tightly closed.

50 mg

36 months

ZheJiang Otsuka Pharmaceutical Co., Ltd.

• Founded in:

  1991-10-12

• Address:

  No. 1 Shangguafan, Jinnan Street, Lin'an District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330100609129453D

• Registered Funds:

  $54,333,333

• Email:

  Log in to view